Charles River Laboratories International Galapagos Transaction Update

On March 13 Charles River announced the acquisition of Galapagos NV’s CRO services businesses: Argenta and BioFocus.

To finance the acquisition, Charles River used a combination of cash and debt from its existing euro-denominated revolving credit facility. As a result, we estimate 2014 interest expense will increase by $2.8 million, to $9.6 million.

CRL trades at 19.4 times current 2014 EPS estimated of $3.15, which is well above its five-year average of 14.0 times (range 10 to 19 times) but well below the CRO group average of 23.8 times. We are pleased by signs of improvement in early-stage drug development and encouraged by this addition to CRL’s portfolio. However, the historically high valuation and ongoing pressure on the core model business give us pause.

Related posts


Warren Buffett's Best Picks

Warren Buffett's these stock picks will crush the market over the next 12 months. Get our report FREE by becoming a member now